This technology is an in vitro assay for quantitatively screening patient phagocytic immune cell dysfunction as a means of assessing risk for autism spectrum disorder (ASD).
Diagnosis for ASD currently relies on qualitative behavioral tests that are unfeasible during infancy, when early intervention has the greatest chance of success. As such, there is a need for a quantitative method that would enable early detection of ASD.
This technology enables early detection of ASD by assessing immune cell function in patient blood samples using an in vitro assay. This technology has demonstrated that ASD is associated with compromised brain and blood phagocytic immune cell function. Screening for these defects during infancy could serve as a quantitative means of assessing patient risk for ASD, enabling early intervention before symptoms progress. By enabling diagnosis before behavioral tests are possible, this technology could serve as a powerful tool for the treatment and management of ASD.
IR CU17107
Licensing Contact: Ron Katz